JPRN-UMIN000016152
Recruiting
未知
Multi-Center Study of Aflibercept Therapy for Neovascular Age-Related Macular Degeneration Using Trreat and Extend Strategy - Treat & Extend Stratedy with Aflibercept for AMD
Tokyo Women's Medical University0 sites200 target enrollmentJanuary 7, 2015
Overview
- Phase
- 未知
- Intervention
- Not specified
- Conditions
- eovascular age-related macular degeneration
- Sponsor
- Tokyo Women's Medical University
- Enrollment
- 200
- Status
- Recruiting
- Last Updated
- 2 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- Not provided
Exclusion Criteria
- •1\. Local Steroid Therapy within 3 momths 2\. Previous history of anti\-VEGF treatments 3\. Past history of photodynamic therapy 4\. Severe cataract 5\. Local or systemic infection 6\. Hisrory of uveitis 7\. Apahakic eyes 8\. Uncontrolled hypertension 9\. Cerebrovascular or cardiac vascular accident within 6 months 10\. Renal failure requiring dyalisis 11\. Allegy for fluorescsin and indocyaningreen dye 12\. Pregnancy or lactating 13\. Other conditions that the principal investigator points out
Outcomes
Primary Outcomes
Not specified
Similar Trials
Completed
Not Applicable
Investigation of clinical efficacy for Aflibercept in patients with polypoidal choroidal vasculopathy (PCV)Polypoidal Choroidal VasculopathyJPRN-UMIN000011091Department of Ophthalmology, Graduate School of Medical Sciences, Kyushu University50
Recruiting
Phase 4
Prospective study evaluating aflibercept in patients with recurrent or prolonged diabetic macular edema after vitrectomyDiabetic macular edemaJPRN-UMIN000016036Kyushu university30
Completed
Not Applicable
Investigation of clinical efficacy of aflicbercept in patients with polypoidal choroidal vasculopathy (PCV) with resistance of ranibizumabPolypoidal choroidal vasculopathyJPRN-UMIN000012493Department of Ophthalmology, Graduate School of Medicine, The University of Tokyo30
Active, not recruiting
Phase 1
Aflibercept Efficacy in Patients Suffering Age-Related Damage of the Yellow Spot of the Light-sensitive Tissue Layer in the EyeEUCTR2014-002168-34-CZDoc. MUDr. Petr Kolár, PhD, Ocní klinika FN Brno45
Active, not recruiting
Phase 1
AUSCorEUCTR2014-002003-25-GBBarts Health NHS Trust54